Targeting survivin in cancer: The cell-signalling perspective

Drug Discovery Today

Volumn 16, Issue 11-12, 2011, Pages 485-494

  Kanwar, Jagat R ^a   Kamalapuram, Sishir K ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 1 (2 METHOXYETHYL) 2 METHYL 4,9 DIOXO 3 (PYRAZIN 2 YLMETHYL) 4,9 DIHYDRO 1H NAPHTHO[2,3 D]IMIDAZOLIUM BROMIDE; 15 DEOXY DELTA(12,14)PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; ANTISENSE SURVIVIN; ANTISURVIVIN AMINO SILICA; ANTISURVIVIN OLIGONUCLEOTIDE; BATABULIN; CURCUMIN; GELDANAMYCIN; IMATINIB; IMIDAZOLE DERIVATIVE; IRINOTECAN; LONAFARNIB; MEVINOLIN; OLIGONUCLEOTIDE; PROSTAGLANDIN; QUERCETIN; SALIRASIB; SILICON DIOXIDE; SMALL INTERFERING RNA; SN8; SURVIVIN; TRASTUZUMAB; TRICIRIBINE; TROGLITAZONE; UNCLASSIFIED DRUG;

CANCER RESISTANCE; DRUG TARGETING; GENE THERAPY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79958237620     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.04.001     Document Type: Review

References (88)

1. M.E. Johnson, and E.W. Howerth Survivin: a bifunctional inhibitor of apoptosis protein Vet. Pathol. 41 2004 599 607 (Pubitemid 39573750)
2. C.H. Cheung A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy Cancer Cell Int. 10 2010 36
3. J.R. Kanwar Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy J. Natl. Cancer Inst. 93 2001 1541 1552 (Pubitemid 32998483)
4. D.C. Altieri New wirings in the survivin networks Oncogene 27 2008 6276 6284
5. V. Vaira Regulation of survivin expression by IGF-1/mTOR signaling Oncogene 26 2007 2678 2684 (Pubitemid 46663841)
6. S.H. Oh Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression Clin. Cancer Res. 14 2008 1581 1589
7. S. Baratchi Survivin: a target from brain cancer to neurodegenerative disease Crit. Rev. Biochem. Mol. Biol. 45 2010 535 554
8. L.F. Fan Role of Hypoxia-inducible factor-1 alpha and Survivin in colorectal carcinoma progression Int. J. Colorectal Dis. 23 2008 1057 1064
9. S. Mamori Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition World J. Gastroenterol. 13 2007 5306 5311 (Pubitemid 47559459)
10. J.R. Kanwar Targeting survivin in cancer: patent review Expert Opin. Ther. Pat. 20 2010 1723 1737
11. G.W. Krissansen Tumor Treating Combinations, Compositions and Methods 2005
12. P. Fortugno Regulation of survivin function by Hsp90 Proc. Natl. Acad. Sci. U. S. A. 100 2003 13791 13796 (Pubitemid 37499145)
13. C.H.A. Cheung Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells Mol. Cancer 9 2010 77
14. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat. Rev. Cancer 9 2009 550 562
15. X.H. Peng Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression J. Biol. Chem. 281 2006 25903 25914
16. K.M. Debatin Endothelial progenitor cells for cancer gene therapy Gene Ther. 15 2008 780 786
17. H. Asanuma Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells Cancer Res. 65 2005 11018 11025 (Pubitemid 41713372)
18. G. Melillo Targeting hypoxia cell signaling for cancer therapy Cancer Metastasis Rev. 26 2007 341 352 (Pubitemid 47101663)
19. J. Lu Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance Clin. Cancer Res. 15 2009 1326 1334
20. Q. Jin Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure Carcinogenesis 29 2008 1614 1622
21. E. Drakos Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas Expert Rev. Mol. Med. 10 2008 e4
22. H.Y. Zhang Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy Eur. J. Obstet. Gynecol. Reprod. Biol. 146 2009 81 86
23. B.Z. Carter Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Blood 107 2006 1555 1563 (Pubitemid 43242394)
24. X. Ling Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G(2)/M arrest J. Biol. Chem. 279 2004 15196 15203 (Pubitemid 38618915)
25. R Blum Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis Mol. Cancer Ther. 5 2006 2337 2347 (Pubitemid 44530471)
26. Y.H. 2Kim Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway Biochem. Pharmacol. 75 2008 1946 1958
27. J.G. Wu Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin - evidence of survivin down-regulation associated with drug sensitivity J. Biol. Chem. 280 2005 9745 9751
28. N.H Nabilsi DNA methylation inhibits p53-mediated survivin repression Oncogene 28 2009 2046 2050
29. M. Guha Endogenous tumor suppression mediated by PTEN involves survivin gene silencing Cancer Res. 69 2009 4954 4958
30. S. Erkanli Expression of survivin PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium Int. J. Gynecol. Cancer 16 2006 1412 1418 (Pubitemid 43886778)
31. J. Tan Regulation of survivin and Bcl-2 in HepG2 cell apoptosis induced by quercetin Chem. Biodivers. 6 2009 1101 1110
32. J.L. Watson Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling Mol. Carcinog. 49 2010 13 24
33. J.J. Liu Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro Ann. Oncol. 16 2005 455 459 (Pubitemid 40458324)
34. Z. Wang TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway Cancer Res. 69 2009 2757 2765
35. A. Jayanthan Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737 Leukemia Lymphoma 50 2009 1174 1182
36. R. Kaneko Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer J. Biol. Chem. 282 2007 19273 19281 (Pubitemid 47100098)
37. R. Blum Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid) Cancer Res. 67 2007 3320 3328 (Pubitemid 46724871)
38. C.H.A. Cheung A cell-permeable dominant-negative Survivin protein as a tool to understand how Survivin maintains tumour cell survival Eur. J. Cancer Suppl. 4 2006 149 1149
39. R.K. Kanwar Recent advances in anti-survivin treatments for cancer Curr. Med. Chem. 2010
40. S. Baratchi Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress PLoS ONE 6 2011 e15865
41. S. Baratchi Proliferative and protective effects of SurR9-C84A on differentiated neural cells J. Neuroimmunol. 227 2010 120 132
42. S. Baratchi Survivin: a target from brain cancer to neurodegenerative disease Crit. Rev. Biochem. Mol. Biol. 45 2010 535 554
43. Sara Baratchi Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity J. Neuroimmunol. 233 2010 18 28
44. I. Jutooru Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation J. Biol. Chem. 285 2010 25332 25344
45. A.R. Hussain Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias Apoptosis 11 2006 245 254 (Pubitemid 43291024)
46. C. Zhang Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling J. Invest. Dermatol. 130 2010 2110 2119
47. R.V. Priyadarsini The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells Free Radic. Res. 44 2010 624 634
48. G. Harish-Kumar The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis Invest. New Drugs 28 2010 392 401
49. Q.Q. Guo Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition Biochem. Pharmacol. 77 2009 1674 1683
50. X. Wang Application of nanotechnology in cancer therapy and imaging CA Cancer J. Clin. 58 2008 97 110 (Pubitemid 351521865)
51. S. Baratchi Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases Curr. Nanosci. 5 2009 15 25
52. J.R. Kanwar Recent advances in nanoneurology for drug delivery to the brain Curr. Nanosci. 5 2009 441 448
53. C. Mohanty Receptor mediated tumor targeting: an emerging approach for cancer therapy Curr. Drug Deliv. 8 2010 45 58
54. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
55. Mahidhara, G. et al. A novel nanoplatform for oral delivery of anti-cancer biomacromolecules. Int. J. Nanotechnol. (in press)
56. J.R. Kanwar Antiangiogenic therapy using nanotechnological-based delivery system Drug Discov. Today 16 2011 188 202
57. R. Bawa NanoBiotech 2008: exploring global advances in nanomedicine Nanomed. Nanotechnol. Biol. Med. 5 2009 5 7
58. Kanwar, R.K. et al. (2010) Preparation and characterization of SurR9-C84A loaded polymeric nano carriers for oral delivery in colon cancer. Nanomedicine (in press)
59. L.S. Jabr-Milane Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat. Rev. 34 2008 592 602
60. K. Park New generation of multifunctional nanoparticles for cancer imaging and therapy Adv. Funct. Mater. 19 2009 1553 1566
61. J.D. Byrne Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
62. B. Pan Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system Cancer Res. 67 2007 8156 8163 (Pubitemid 47395151)
63. Y. Chen, and L. Huang Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy Expert Opin. Drug Deliv. 5 2008 1301 1311
64. S.D. Li, and L. Huang Surface-modified LPD nanoparticles for tumor targeting Ann. N. Y. Acad. Sci. 1082 2006 1 8 (Pubitemid 44955442)
65. S.D. Li, and L. Huang Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells Mol. Pharm. 3 2006 579 588 (Pubitemid 44639135)
66. J. Peng An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells Nanomedicine 2 2006 113 120 (Pubitemid 43956609)
67. D.S. Seferos Locked nucleic acid-nanoparticle conjugates Chembiochem 8 2007 1230 1232 (Pubitemid 47171986)
68. Z. Medarova In vivo imaging of siRNA delivery and silencing in tumors Nat. Med. 13 2007 372 377 (Pubitemid 46376679)
69. A. Nan Multifunctional nanocarrier for image-guided delivery of bioactive agents Nanomedicine (Lond.) 2 2007 739 743 (Pubitemid 350268251)
70. M. Pennati Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis 28 2007 1133 1139 (Pubitemid 47062670)
71. T. Nakahara YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res. 67 2007 8014 8021 (Pubitemid 47395135)
72. T. Iwasa Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines Clin. Cancer Res. 14 2008 6496 6504
73. A.C. Mita Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics Clin. Cancer Res. 14 2008 5000 5005
74. C.H. Cheung Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers Mol. Cancer 8 2009 43
75. X. Ling Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin Am. J. Transl Res. 1 2009 393 405
76. P. Bischoff Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers Expert Opin Ther. Pat. 19 2009 643 662
77. B.H. Kang Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90 J. Clin. Invest. 119 2009 454 464
78. Y. Huang Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma Cell Res. 18 2008 780 791 (Pubitemid 351948227)
79. J. Lin Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways Clin. Cancer Res. 16 2010 77 87
80. T. Shinjyo Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells Tohoku J. Exp. Med. 216 2008 25 34
81. Z. Khan Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings Head Neck 31 2009 1039 1048
82. F. Vegran Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer Oncogene 26 2007 290 297 (Pubitemid 46095740)
83. E.M. Hammond, and A.J. Giaccia The role of p53 in hypoxia-induced apoptosis Biochem. Biophys. Res. Commun. 331 2005 718 725 (Pubitemid 40615503)
84. B. Sung Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther. 8 2009 959 970
85. F.M. Uckun STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress Proc. Natl. Acad. Sci. U. S. A. 107 2010 2902 2907
86. K.W. Sommer Oncogenic c-H-ras deregulates survivin expression: an improvement for survival FEBS Lett. 581 2007 4921 4926 (Pubitemid 47531763)
87. Y. Matsuo K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways Mol. Cancer Res. 7 2009 799 808
88. M. Okuya Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells J. Biol. Chem. 285 2010 1850 1860